Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver.

Liver international : official journal of the International Association for the Study of the Liver - 1 Nov 2012

Leroy Vincent, Serfaty Lawrence, Bourlière Marc, Bronowicki Jean-Pierre, Delasalle Patrick, Pariente Alexandre, Pol Stanislas, Zoulim Fabien, Pageaux Georges-Philippe

Abstract excerpt

The recent marketing authorizations and hence availability of the new protease inhibitors, telaprevir and boceprevir, have profoundly changed the management of chronic hepatitis C patients. Guidelines for the use of these new drugs as part of a triple therapy, in combination with the standard therapy of peginterferon plus ribavirin, are proposed. The guidelines have been drawn up and evaluated by a meeting of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Combinations
Share to Interferons

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukins

Share to Oligopeptides

Share to Polyethylene Glycols

Share to Proline

Share to Protease Inhibitors

Share to Ribavirin

Source

Identifiers

PMID: 22891751
DOI: 10.1111/j.1478-3231.2012.02856.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver.PMID 22891751Read ↗

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.Semantic proximity Read ↗

Update of the Belgian Association for the Study of the Liver guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors.Semantic proximity Read ↗

[Treatment guidelines for patients with genotype 1 chronic hepatitis C infection].Semantic proximity Read ↗

Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.Semantic proximity Read ↗

Treatment of hepatitis C monoinfection in adults--Dutch national guidelines.Semantic proximity Read ↗

Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil.Semantic proximity Read ↗

[Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].Semantic proximity Read ↗

A review of standard and newer treatment strategies in hepatitis C.Semantic proximity Read ↗

An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.Semantic proximity Read ↗

[Triple therapy in cirrhotic patients and those with advanced fibrosis: relevant aspects in clinical practice].Semantic proximity Read ↗

2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines.Semantic proximity Read ↗

Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.